Harbin Gloria Pharmaceuticals (002437) - Total Liabilities
Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) has total liabilities worth CN¥735.96 Million CNY (≈ $107.69 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Harbin Gloria Pharmaceuticals to track the company's year-over-year net asset growth rate.
Harbin Gloria Pharmaceuticals - Total Liabilities Trend (2007–2025)
This chart illustrates how Harbin Gloria Pharmaceuticals's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Harbin Gloria Pharmaceuticals generate to measure how efficiently the company converts operating cash flow to free cash.
Harbin Gloria Pharmaceuticals Competitors by Total Liabilities
The table below lists competitors of Harbin Gloria Pharmaceuticals ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Southern Cross Electrical Engineering Ltd
AU:SXE
|
Australia | AU$197.61 Million |
|
Shantou Dongfeng Printing Co Ltd
SHG:601515
|
China | CN¥1.25 Billion |
|
AMG Advanced Metallurgical Group NV
AS:AMG
|
Netherlands | €1.63 Billion |
|
Sedlmayr Grund und Immobilien AG
F:SPB
|
Germany | €980.61 Million |
|
Grindrod
JSE:GND
|
South Africa | ZAC6.16 Billion |
|
Medartis Holding AG
SW:MED
|
Switzerland | CHF284.05 Million |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥2.75 Billion |
|
Sichuan Crun Co Ltd
SHE:002272
|
China | CN¥2.11 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Harbin Gloria Pharmaceuticals's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Harbin Gloria Pharmaceuticals stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harbin Gloria Pharmaceuticals's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harbin Gloria Pharmaceuticals (2007–2025)
The table below shows the annual total liabilities of Harbin Gloria Pharmaceuticals from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥825.00 Million ≈ $120.72 Million |
-3.20% |
| 2024-12-31 | CN¥852.26 Million ≈ $124.71 Million |
-40.91% |
| 2023-12-31 | CN¥1.44 Billion ≈ $211.04 Million |
-39.16% |
| 2022-12-31 | CN¥2.37 Billion ≈ $346.90 Million |
-12.72% |
| 2021-12-31 | CN¥2.72 Billion ≈ $397.47 Million |
+5.14% |
| 2020-12-31 | CN¥2.58 Billion ≈ $378.03 Million |
-46.39% |
| 2019-12-31 | CN¥4.82 Billion ≈ $705.18 Million |
-5.20% |
| 2018-12-31 | CN¥5.08 Billion ≈ $743.86 Million |
+5.65% |
| 2017-12-31 | CN¥4.81 Billion ≈ $704.09 Million |
+4.15% |
| 2016-12-31 | CN¥4.62 Billion ≈ $676.04 Million |
-4.66% |
| 2015-12-31 | CN¥4.85 Billion ≈ $709.06 Million |
+166.22% |
| 2014-12-31 | CN¥1.82 Billion ≈ $266.35 Million |
+291.77% |
| 2013-12-31 | CN¥464.60 Million ≈ $67.99 Million |
+127.98% |
| 2012-12-31 | CN¥203.79 Million ≈ $29.82 Million |
+77.35% |
| 2011-12-31 | CN¥114.91 Million ≈ $16.81 Million |
+55.85% |
| 2010-12-31 | CN¥73.73 Million ≈ $10.79 Million |
-52.42% |
| 2009-12-31 | CN¥154.95 Million ≈ $22.67 Million |
+81.94% |
| 2008-12-31 | CN¥85.17 Million ≈ $12.46 Million |
+10.39% |
| 2007-12-31 | CN¥77.15 Million ≈ $11.29 Million |
-- |
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more